O BJECTIVES : To describe, in a cohort of dogs with presumed primary immune-mediated neutropenia, the presenting clinical characteristics, haematology results, bone marrow characteristics, therapies used (drugs and doses), clinical response to treatment, relapse and outcome at six months and one year. 
INTRODUCTION
Presumptive primary immune-mediated neutropenia (IMN), also known as immune-mediated, idiopathic or corticosteroidresponsive neutropenia, is an uncommon, poorly described disorder in dogs (Chickering & Prasse 1981 , McManus et al . 1999 , Pedersen 1999 , Brown & Rogers 2001 , Perkins et al . 2004 , Brown et al . 2006 , Vargo et al . 2007 , Weiss & Henson 2007 , Schnelle & Barger 2012 . Diagnosis of presumed primary IMN is made on the basis of a neutrophil concentration disproportionately low relative to clinical signs, exclusion of other causes of neutropenia, exclusion of secondary IMN and rapid response to immunosuppressive therapy (McManus et al . 1999 , Brown & Rogers 2001 , Perkins et al . 2004 , Vargo et al . 2007 , Schnelle & Barger 2012 . Secondary IMN has been attributed to drugs, infections or neoplasia (Chickering & Prasse 1981 , McManus et al . 1999 , Brown et al . 2006 , Vargo et al . 2007 ). To our knowledge, the long-term outcome and relapse rate in dogs with presumed primary IMN has not been previously published.
The prevalence of presumed primary IMN has been reported as 0·35% to 7% of dogs examined for neutropenia at referral veterinary hospitals (Brown & Rogers 2001 , Brown et al . 2006 . Fever, lethargy, anorexia, vomiting, lameness and reluctance to rise are the most commonly reported signs of IMN (McManus et al . 1999 , Perkins et al . 2004 , Brown et al . 2006 . Some cases have been diagnosed on the basis of subclinical neutropenia on wellness blood work (Perkins et al . 2004 , Brown et al . 2006 . Myeloid hyperplasia, hypoplasia and aplasia have been identified on bone marrow cytology from dogs with primary IMN (McManus et al . 1999 , Perkins et al . 2004 , Weiss & Henson 2007 .
Antibodies against neutrophils or neutrophil precursors are suspected to form either in the bone marrow or peripheral circulation in dogs with IMN (Chickering & Prasse 1981 , McManus et al . 1999 , Pedersen 1999 , Brown & Rogers 2001 , Perkins et al . 2004 , Vargo et al . 2007 , Weiss 2007a , 2007b , Weiss & Henson 2007 , Schnelle & Barger 2012 . Neutrophil-antibody complexes trigger opsonisation of neutrophils in peripheral circulation and facilitate their removal by macrophages in the liver, spleen, lymph nodes and bone marrow. In human patients, definitive diagnosis requires demonstration of antibodies against neutrophil-specific antigens. In dogs with IMN, immunoglobulin G and C3 antibodies bound to promyelocytes and bone marrow neutrophilic elements have been described (Brown et al . 2006 ) . Indirect immunoassays using flow cytometry have been used to detect anti-neutrophil IgG and C3 antibodies in dogs (McManus et al . 1999 , Vargo et al . 2007 , Weiss 2007a , 2007b , Weiss & Henson 2007 . Indirect flow cytometry is considered the most sensitive test to detect membrane-bound IgG and has been validated for use in dogs ( Weiss 2007a ( Weiss , 2007b . Use of indirect flow cytometry tests is currently limited by the lack of widespread availability and unknown specificity of the test.
In dogs, primary IMN has been described in association with other immune-mediated disease including immune-mediated haemolytic anaemia (IMHA), immune-mediated thrombocytopenia (IMT), non-septic suppurative meningitis, non-septic suppurative polyarthritis, rheumatoid arthritis, systemic lupus erythematosis and hypoadrenocorticism (Brown & Rogers 2001 , Perkins et al . 2004 , Vargo et al . 2007 , Weiss & Henson 2007 , Snead et al . 2011 . It has been postulated that up to 25% of dogs with IMN have concurrent IMT at the time of diagnosis (Perkins et al . 2004 , Brown et al . 2006 , Vargo et al . 2007 ). Unfortunately, the majority of the reports have involved small case numbers with variable work-up and follow-up, limiting development of optimal diagnostic and therapeutic strategies.
The objective of this study, therefore, was to generate a relatively large cohort of dogs with presumed primary IMN in which to describe the presenting clinical characteristics, complete blood count (CBC) results, bone marrow characteristics, therapies used (drugs and doses), clinical response to treatment, relapse and outcome at six months and one year.
MATERIALS AND METHODS
A search of the electronic medical record database at the University of Minnesota Veterinary Medical Center (UMN VMC) was performed to identify neutropenic dogs. Additional cases that met the inclusion criteria, below, were recruited from a posting on the American College of Veterinary Internal Medicine (ACVIM) small animal internal medicine case list serve, and on the Veterinary Information Network (VIN). Inclusion criteria were that the case was diagnosed with presumed primary IMN between January 1, June 30, 2013 , and that a complete medical record was available from that diagnosis onwards. To provide consistency in the diagnosis of neutropenia across multiple laboratories, neutropenia was defined as an absolute neutrophil concentration less than 1·5×10 9 cells/L with an absence of a degenerative left shift. To be included in the study, the dog ' s medical record needed to include a minimum of two CBCs documenting mature neutropenia prior to the initiation of immunosuppressive therapy, with at least one of the CBCs, including evaluation of a blood smear, performed by a commercial or university reference laboratory, and a diagnostic bone marrow aspirate or biopsy interpreted by a commercial or academic reference laboratory. Reticulocyte concentrations were not required. Dogs with concurrent thrombocytopenia were included given the high prevalence of concurrent thrombocytopenia previously reported in case series of canine IMN. A minimum of two CBCs performed after initiation of therapy, typically within 2-4 weeks of treatment, was also required for inclusion. A minimum followup period was not a requirement.
Exclusion criteria included any of the following at the time that neutropenia was documented: non-dermatologic infectious disease, neoplasia, immune-mediated disease(s) other than IMT, or myelophthetic disease (such as myelofibrosis or granulomatous myelitis), a haematocrit less than 29% or a degenerative left shift (absolute numbers of band neutrophils greater than the absolute numbers of segmented neutrophils). Also excluded were dogs with exposure to glucocorticoids or to known myelosuppressive drugs (e.g. oestrogens, antineoplastic agents, non-glucocorticoid immunosuppressants, etc.) within one month before documentation of neutropenia.
Information retrieved from medical records for the visit at which IMN was diagnosed included age, sex, breed, presenting complaint(s), clinical signs and prior drug administration. Body temperature, abnormal physical examination findings and results of diagnostic testing, including imaging and anti-neutrophil antibody results when available, performed prior to initiation of therapy for IMN were recorded. An increase in body temperature was defined as a core body temperature greater than 39°C. Serum chemistry analyses were performed by commercial or university reference laboratories in almost all cases. Results were compared to individual laboratory reference intervals. Imaging and ancillary testing were typically performed at the referral institution. Pretreatment CBC findings from reference or university analysers were used. Given that haematology reference intervals and medical decision points are relatively consistent across laboratories, absolute leucocyte counts and haematocrit percentages were used for analysis (Latimer 2012 ) .
Follow-up neutrophil concentrations were recorded as close to two weeks, one month, six months, and one year after initiation of therapy as medical records allowed. Initial treatments prescribed, and dosages were recorded. Follow-up information for most cases was available. Case outcome at 30 days, six months and one year was categorised as neutrophil concentration greater than 1·5×10 9 cells/L without ongoing glucocorticoid or adjunctive immunosuppressive therapy, neutrophil concentration greater than 1·5×10 9 cells/L on variable dosages of glucocorticoids or adjunctive immunosuppressive therapy, neutropenia (<1·5×10 9 cells/L) while receiving glucocorticoid therapy or adjunctive immunosuppressive therapy or lost to follow-up. Relapse was defined as recurrence of neutropenia less than 1·5×10 9 cells/L after a neutrophil concentration within the reference range had been documented. If relapse occurred, time of relapse following initiation of therapy, and therapeutic response to additional therapy(s) were recorded.
RESULTS
A total of 35 dogs were included in the study. Medical records of 115 dogs with neutropenia admitted to the UMN VMC, and 48 additional dogs (45 from ACVIM list serve and three from VIN) were reviewed. Five out of 115 neutropenic dogs from the UMN VMC database were considered for inclusion. Upon further evaluation, two of the 115 neutropenic dogs (1·7%) from the UMN VMC database met the inclusion criteria. A total of 18 cases were excluded for one or more reasons. Figure 1 summarises reasons for case exclusion.
Of the 35 dogs, the breed distribution was shih-tzu (4), retriever mix (3), Labrador retriever (3), mixed breed (3), beagle (2), Lhasa apso (2), and one each of Australian shepherd, cairn terrier, cocker spaniel, great Pyrenees, greyhound, Irish setter, Italian greyhound, lurcher, mastiff, papillon, pit bull, saluki, springer spaniel, dachshund, giant schnauzer, maltese, Chesapeake Bay retriever and toy poodle. There were 22 spayed female, 12 neutered male and one intact male dog (Table 1 ) . Median age at diagnosis was 5 years (range 1 to 12).
Four dogs (11%) in which the owners denied any clinical signs had neutropenia diagnosed on wellness blood work. Three of these four dogs had an increase in body temperature (temperature>39°C) upon presentation. Presenting clinical complaints and physical examination findings recorded in two or more dogs are summarised in Table 1 . Lethargy and anorexia were the most common presenting complaints, each present in 63% of cases. An increase in body temperature was present in almost half the cases (46%). Clinical findings recorded in one case each were dehydration, melaena, cough, temporal muscle pain, irritated eyes, shifting leg lameness and wheezing. When recorded, the duration of clinical signs prior to evaluation by the referring veterinarian varied from 0-2 months. Thirteen dogs had clinical signs less than one week, six dogs had clinical signs for 1-2 weeks, two dogs had clinical signs for 2-4 weeks and four dogs had clinical signs for more than four weeks. The duration of clinical signs could not be determined from the medical record in nine dogs. Treatments administered within one month before referral were antimicrobials (20 dogs), nonsteroidal anti-inflammatories (6), antiemetics (4), H 2 antagonists (3), proton pump inhibitor (2), diphenhydramine (1), phenylpropanolamine (1) and potassium bromide (1).
Selected CBC parameters available for each dog prior to the initiation of treatment are shown in Table 2 . An increased band neutrophil concentration was observed in four out of 22 dogs for which such data were available. Results from serum biochemical analyses were available for all 35 dogs. Abnormalities included increased serum alkaline phosphatase activity (16 dogs), hypoalbuminaemia (10), increased serum alanine transanimase activity (5), hyperglobulinaemia (5), hyponatraemia (5), hypokalaemia (5), hypocalcaemia (5), hypomagnesaemia (4), hypoproteinaemia (4), hypophosphataemia (3) and decreased blood urea nitrogen (2).
Bone marrow aspirates were obtained in all 35 dogs. Bone marrow core analysis was also obtained in 13 dogs (37%). Bone marrow aspiration findings are reported in Table 3 . Of the 23 dogs with myeloid hyperplasia, seven had a left shift in maturation. Erythroid hyperplasia was noted in five dogs. Two of five had a left shift in erythroid maturation; only one of these dogs was anaemic. Three of the seven dogs with erythroid hypoplasia were anaemic. Ten dogs had megakaryocytic hyperplasia, half of which were thrombocytopenic, whereas one dog had megakaryocytic hypoplasia. Less common findings included fibrosis (two dogs), necrosis (2), edema (1), and myeloid dysplasia (1). One dog had a normal bone marrow core analysis (1), and another had a nondiagnostic bone marrow core sample.
Other laboratory testing varied among cases, but most diagnostic evaluations included urinalysis, urine culture and vector-borne disease testing. Anti-neutrophil antibody testing was positive in five of nine dogs (56%) tested. A 4DX SNAP test ( Ehrlichia canis , Borrelia burgdorferi , Anaplasma phagocytophilum and Dirofilaria immitis ; IDEXX Laboratories) was performed in 14 dogs. Serum indirect fluorescence (IFA) titers for various vector-borne diseases based on geographic prevalence and patient risk factors were performed in eight dogs. Both 4DX SNAP test and vector-borne serology were performed in four additional dogs. Other ancillary evaluation in some cases included antimegakaryocyte (1), and antinuclear antibody (2) testing; blood cultures (4); leptospirosis serology (1); baseline cortisol concentrations (1); Blastomyce s urine antigen test (3); Histoplasma antibody titers (3); faecal analysis and culture (3) and culture and/or cytology from the nasal passages (1), transtracheal wash sample (1), or lymph node (1). A SNAP cPL (IDEXX Laboratories) test was positive in one of two dogs tested.
Diagnostic imaging performed in one or more cases during initial examination included abdominal ultrasound (33); radiographs of the thorax (27), abdomen (21), lumbosacral spine (1), tarsus (1) and pelvis (1); echocardiogram (2); skull computed tomography (1) and rhinoscopy (1). Abdominal ultrasound was unremarkable in 11 of 33 dogs (33%) evaluated. The most common findings were splenomegaly (3), chronic renal degenerative changes (3), mottled spleen (3), splenic nodule (2) and lymphadenomegaly (2). Multiple peripheral lymph node aspirates were performed in one dog with lymphadenomegaly noted on abdominal ultrasound. Cytology was consistent with reactive hyperplasia with pyogranulomatous lymphadenitis. Abdominal lymph node aspirates were not obtained in the second dog due to severe thrombocytopenia; however, bone marrow biopsies were not consistent with lymphoma. Thoracic radiographs were reported as unremarkable in 22 of 27 dogs (82%). The remaining five dogs had minor changes not compatible with neoplasia or infectious disease. Abdominal radiographs were unremarkable in 10 of 21 dogs (48%) evaluated. The most common abnormality was splenomegaly (5).
As required by the inclusion criteria, immunosuppressive therapies were administered to all 35 dogs. Thirty of 35 dogs (86%) were initially started on prednisone or prednisolone orally (median 2 mg/kg/day, dosage range 0·5 to 5 mg/kg/day). The remaining five dogs (14%) were started on dexamethasone intravenously (median 0·2 mg/kg/day, dosage range 0·07 to 0·4 mg/ kg/day), and later changed to prednisone orally for long-term therapy. Adjunctive immunosuppressive medation was initiated in 15 out of 35 dogs (43%) during treatment: azathioprine in 10 dogs and cyclosporine (Atopica, Novartis) in six dogs. Additional immunosuppressive mediations were added at the time of diagnosis for five dogs, later as additional therapy in conjunction with corticosteroid therapy for five dogs or after relapse of neutropenia in five dogs. Antibiotics were administered in 23 dogs (66%). Fifteen dogs were lost to follow up by one year (two dogs by one month, five dogs by six months and eight dogs by 12 months), and one dog was euthanased due to the development of a hepatic abscess 280 days into therapy. The time course for tapering immunosuppressive medications varied from 1-6 months. Thirty-two of 33 dogs (97%) had greater than 1·5×10 9 neutrophils/L within two weeks of initiating corticosteroid therapy (Fig 2 ) . Data were not available in two dogs for this time point. At one month, 31 of 31 dogs (100%) had greater than 1·5×10 9 neutrophils/L on variable dosages of glucocorticoids. Data were not available for this time point in two dogs, and two dogs had been lost to follow-up. The platelet concentration normalised in five of eight thrombocytopenic dogs within one month. One dog was lost to follow up and the platelet count was unavailable in the remaining two dogs. At six months, neutrophil concentrations remained greater than 1·5×10 9 cells/L in 17 of 27 (63%) on variable dosages of glucocorticoids, and 10 of 27 (37%) were no longer receiving ongoing glucocorticoid or adjunctive immunosuppressive therapy. An additional five dogs were lost to follow-up by the 6-month time period, and data were not available in one dog. At one year, data from 19 dogs were available for review. Twelve of 19 dogs (63%) had neutrophil concentrations greater than 1·5×10 9 cells/L while receiving ongoing immunosuppressive therapy; seven of 19 (37%) had neutrophil concentrations greater than 1·5×10 9 cells/L without receiving ongoing glucocorticoid therapy. One dog developed IMHA and IMT two months after discontinuation of prednisone, but neutrophil concentrations remained within the reference interval. Relapse of neutropenia was observed in 12 of 35 (34%) dogs. Seven relapses occurred during the tapering of corticosteroids or adjunctive immunosuppressive therapy, and five relapses occurred following discontinuation of corticosteroid or adjunctive immunosuppressive therapy. Four out of five dogs for which adjunctive immunosuppressive therapy was added due to relapse of neutropenia developed another DISCUSSION IMN has been infrequently described in the veterinary literature (Chickering & Prasse 1981 , McManus et al . 1999 , Brown et al . 2006 , Vargo et al . 2007 , Weiss & Henson 2007 . Our study provides clinical, outcome, and relapse data on a cohort of 35 dogs with IMN, obtained from records at multiple institutions and practices. Our data show that dogs with IMN can have initial excellent response rates to corticosteroid treatment. Almost all study dogs had a normal to increased neutrophil concentration within two weeks of introducing corticosteroid therapy. Interestingly, dogs responded over a wide dose range of corticosteroid administered (0·5 to 5 mg/kg/day prednisone or prednisolone). The one dog treated with prednisone at 0·5 mg/kg/day failed to respond to therapy but within two weeks had a normal neutrophil concentration after a dose increase to 2 mg/kg/day. Four additional dogs started on sub-immunosuppressive dosages of prednisone (1 to 1·5 mg/kg/day) all responded with normal to increased neutrophil concentrations within two weeks of therapy. Continued neutrophil response rates were similarly favourable at six months, and one year for all dogs remaining in the study. However, 17 of 27 dogs (63%) at six months and 12 of 19 dogs (63%) at one year required ongoing corticosteroid administration to maintain normal neutrophil concentration. The high percentage of dogs still undergoing corticosteroid therapy at six months could reflect differences in protocols used to taper immunosuppressive medications. The relapse rate was high with 12 of 35 (34%) dogs experiencing neutropenia at some point during or after tapering corticosteroid therapy. Further, four out of five dogs had additional episodes of neutropenia relapse despite the addition of adjunctive immunosuppressive therapy.
This may reflect a subset of the population refractory to treatment. IMN is typically a diagnosis of exclusion. Serum chemistry analysis, imaging and ancillary testing, such as vector-borne disease testing, were performed in the majority of cases without revealing an underlying cause of the neutropenia. Additionally, historical questions regarding medication and supplement history may be crucial to evaluate for a possible underlying inciting event. Indirect flow cytometry and leucoagglutination have been used to identify anti-neutrophil antibodies in dogs, cats and horses (McManus et al . 1999 , Perkins et al . 2004 , Weiss 2007b , Weiss & Henson 2007 . Identification of anti-neutrophil antibodies might provide a more definitive means of confirming a diagnosis of IMN, although it cannot distinguish between primary and secondary disease (Weiss 2007a , Weiss & Henson 2007 . Additionally, detection of anti-neutrophil antibodies can be challenging due to cell fragility, aggregation in vitro and the release of autolytic enzymes when handled (Chickering & Prasse 1981 , Shastri & Logue 1993 , Brown & Rogers 2001 , Brown et al . 2006 . Marked neutropenia can result in false-negative flow cytometry results (Weiss 2007b , Snead et al . 2011 . The majority of cases in this report did not have anti-neutrophil antibody testing performed, and 4 of 9 (44%) dogs tested had a negative test. This is the largest study reporting bone marrow findings in dogs with presumed primary IMN. Two-thirds of dogs in the study had myeloid hyperplasia, suggesting destruction of later stage or older neutrophils outside the bone marrow. In approximately one third of cases, myeloid hypoplasia and/or maturation arrest were present, consistent with destruction of earlier myeloid precursors. The marrow lymphocytosis and plasmacytosis observed in some dogs could be nonspecifically associated with immune-mediated destruction of haematopoietic cells in the marrow rather than occult neoplasia. Megakaryocytic hyperplasia observed in five of eight thrombocytopenic dogs is consistent with an appropriate 
